Age

18–65

Sex

ALL

Healthy volunteers

Not accepted

Diagnosis of schizophrenia (DSM-IV criteria)
Stable doses of antipsychotic medication (olanzapine, risperidone)for at least 60 days prior to study initiation
Presence of significant negative symptoms (defined as one or more negative symptom score grater than 4 in the PANSS scale) (Kay 1987)
Patients have to give written informed consent to participate in the study

Patients with a substance abuse/dependence diagnosis in the previous six months.
Mental Retardation.
Patients taking antidepressant in the last 4 months before the trial.
Patients taking other antipsychotic medication, except: sinquan 100, Entumine 40, Largactil 100 and Seroquel 200.
Patients who score more than 20 in Hamilton Rating Scale for Depression.
Pregnancy or lactation.
Serious impaired kidney function.
History of hemorrhagic disorders.
Reboxetine or citalopram allergy.

Reboxetine and Citalopram as an Adjunct Treatment to Second Generation Antipsychotics in the Treatment of Negative Symptoms of Schizophrenia